Founded with a mission to deliver curative medicine, Orca Bio is a clinical-stage cell therapy company focused on developing precision allogeneic cell therapies. The company aims to revolutionize the treatment of over 100 malignant and autoimmune diseases through its proprietary technologies. Orca Bio's innovative approach seeks to redefine traditional transplant processes, offering next-generation cell therapies that promise significantly improved patient outcomes.
Orca Bio has assembled a team of world-leading experts and technologists to drive its vision forward. The company has garnered attention for its promising clinical programs, including Orca-T and Orca-Q, which have shown positive data at the 65th ASH Annual Meeting. With its cutting-edge research and impactful clinical results, Orca Bio is poised to make a significant impact in the field of cell therapy, offering new hope to patients worldwide.
